Pramipexole
- Generic Name
- Pramipexole
- Brand Names
- Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N3S
- CAS Number
- 104632-26-0
- Unique Ingredient Identifier
- 83619PEU5T
- Background
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...
- Indication
This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00133198
- Locations
- 🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States
🇺🇸Mid America NeuroScience Institute, Lenexa, Kansas, United States
🇺🇸HealthQuest Clinical Trials Research, San Diego, California, United States
Neuromodulation and Language Acquisition (Stage Ib)
- Conditions
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2010-06-24
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 60
- Registration Number
- NCT00102856
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Lexapro and Pramipexole and to Treat Major Depression
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 39
- Registration Number
- NCT00086307
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Clinical Trial of Pramipexole in Bipolar Depression
- Conditions
- First Posted Date
- 2001-10-25
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 200
- Registration Number
- NCT00025792
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.